NANOV THERAPEUTICS
NanoV Therapeutics develops a novel-mechanism anti-cancer drug. The compound, known as VPOA-6, has demonstrated high effectiveness in inhibiting tumor growth and combating a wide variety of cancers, with much less cytotoxicity than other leading drugs (Cisplatin, one of the most common first-line anti-cancer treatments). NanoV intends to use their newly discovered mechanism, utilizing redox catalysis, to develop a new class of anti-cancer agents to bring life-saving treatment to cancer patients... . With drug resistance becoming a more pronounced obstacle to cancer treatment, novel mechanisms that demonstrate efficacy and safety have the potential to earn a large market. VPOA-6 significantly suppresses a wide range of cancers, including multi-drug resistant types. The synthesis and purification of VPOA-6 are readily accomplished in eco-friendly circumstances, requiring no toxic waste, and costing significantly less than existing cancer drugs.
NANOV THERAPEUTICS
Industry:
Biotechnology Life Science Pharmaceutical
Status:
Active
Total Funding:
24.84 K USD
Similar Organizations
Axcella
Axcella is a biotechnology company providing therapeutics development solutions.
Fertilligen
Fertilligen develops a novel treatment for male infertility.
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
Migra Therapeutics
Migra Therapeutics is developing nanotechnology therapies for cancer.
Neovaccine Strategies
Neovaccine Strategies develops a novel immunotherapeutic reagent to act as a prophylactic against P. aeruginosa.
Oregon Therapeutics
Oregon Therapeutics is a developer of new anti-cancer drugs.
Current Employees Featured
Founder
Investors List
Georgia Research Alliance
Georgia Research Alliance investment in Grant - NanoV Therapeutics